Our pilot study involving a small cohort of 90 cases comprising of 30 AIS patients, 30 BPN patients, and 30 healthy controls (HC), utilizing a chemiluminescence immunoassay, demonstrated that serum IL-6 detection can significantly distinguish the AIS group from the BPN and HC groups. Here, IL6 is linked to androgen insensitivity syndrome.